AA | 05 April 2021 Monday – 17:46 | Last Updated: 05 04 2021 – 17:46
With the research conducted by Manisa Celal Bayar University (MCBÜ) on the immune response of the Sinovac vaccine, it was determined that the vaccine provided 99.2 percent immunity in women and 95.7 percent in men after the second dose.
Turkey on a broad scale used inactivated SARS-CoV-2 Sinovac (Coronavac) vaccine made in the creation of antibodies proficiency study, which was one of the first comprehensive study describes the results in Turkey.
At least 28 days after the first dose of the vaccine, the percentage of immunity was determined as 25.3, while at least 28 days after the second dose, neutralizing quantitative test immunity was 97.92 percent and qualitative test immunity was 97.79 percent.
“Side effects are within acceptable limits”
In the examination of gender groups within the scope of the study, it was determined that the vaccine in question produced more effective antibodies in women. The statement included the following statements:
“Although sufficient percentage of immunity was provided in both genders, a significantly higher vaccine immune response was obtained in women compared to men. Effective antibody response was 29.5% in women, 18.6% in men after the first vaccination, and 99% in women after the second vaccination. These results show that the immunity of the COVID-19 inactive (Sinovac-Coronavac) vaccine, which is applied predominantly in our country, is high and sufficient. However, the adequacy of antibody levels does not guarantee that the person is fully protected from this disease. Personal protection measures should be continued without compromise. Among the results of this research, undesirable vaccine side effects, which will be published separately in scientific meetings and peer-reviewed scientific journals, are within acceptable limits. “